nifedipine has been researched along with Metabolic Syndrome in 3 studies
Nifedipine: A potent vasodilator agent with calcium antagonistic action. It is a useful anti-anginal agent that also lowers blood pressure.
Metabolic Syndrome: A cluster of symptoms that are risk factors for CARDIOVASCULAR DISEASES and TYPE 2 DIABETES MELLITUS. The major components of metabolic syndrome include ABDOMINAL OBESITY; atherogenic DYSLIPIDEMIA; HYPERTENSION; HYPERGLYCEMIA; INSULIN RESISTANCE; a proinflammatory state; and a prothrombotic (THROMBOSIS) state.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The TOlerabilidad de LERcanidipino 20 mg frente a Amlodipino y Nifedipino en CondicionEs normales de uso study was aimed to compare the tolerability of high doses of lercanidipine with amlodipine and nifedipine gastro-intestinal therapeutic system (GITS) in the treatment of hypertension in daily clinical practice." | 9.13 | High doses of lercanidipine are better tolerated than other dihydropyridines in hypertensive patients with metabolic syndrome: results from the TOLERANCE study. ( Barrios, V; Calderón, A; de la Figuera, M; Escobar, C; Honorato, J; Llisterri, JL; Segura, J, 2008) |
| "In patients with MS and mild hypertension monotherapy with spirapril and combination of spirapril with nifedipine retard caused lowering of BP to target level in 55 and 90%, respectively." | 9.12 | [Rational approach to selection of antihypertensive therapy in persons with metabolic syndrome: efficacy of monotherapy with spirapril and its combination with retard form of nifedipine]. ( Kiseleva, NV; Mamedov, MN, 2006) |
| "The TOlerabilidad de LERcanidipino 20 mg frente a Amlodipino y Nifedipino en CondicionEs normales de uso study was aimed to compare the tolerability of high doses of lercanidipine with amlodipine and nifedipine gastro-intestinal therapeutic system (GITS) in the treatment of hypertension in daily clinical practice." | 5.13 | High doses of lercanidipine are better tolerated than other dihydropyridines in hypertensive patients with metabolic syndrome: results from the TOLERANCE study. ( Barrios, V; Calderón, A; de la Figuera, M; Escobar, C; Honorato, J; Llisterri, JL; Segura, J, 2008) |
| "In patients with MS and mild hypertension monotherapy with spirapril and combination of spirapril with nifedipine retard caused lowering of BP to target level in 55 and 90%, respectively." | 5.12 | [Rational approach to selection of antihypertensive therapy in persons with metabolic syndrome: efficacy of monotherapy with spirapril and its combination with retard form of nifedipine]. ( Kiseleva, NV; Mamedov, MN, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Mananko, EI | 1 |
| Vorob'eva, EV | 1 |
| Kalashnikova, TP | 1 |
| Bushkova, EA | 1 |
| Krasnova, NM | 1 |
| Idrisova, EM | 1 |
| Vengerovskiĭ, AI | 1 |
| Karpov, RS | 1 |
| Gruzdeva, OV | 1 |
| Kremenko, SV | 1 |
| Mamedov, MN | 1 |
| Kiseleva, NV | 1 |
| Barrios, V | 1 |
| Escobar, C | 1 |
| de la Figuera, M | 1 |
| Honorato, J | 1 |
| Llisterri, JL | 1 |
| Segura, J | 1 |
| Calderón, A | 1 |
3 trials available for nifedipine and Metabolic Syndrome
| Article | Year |
|---|---|
[The efficiency of combinations of Enalapril and long-acting Nifedipin and Moxonidine in patients with arterial hypertension and a metabolic syndrome].
Topics: Angiotensin-Converting Enzyme Inhibitors; Blood Glucose; Blood Pressure; Blood Pressure Monitoring, | 2008 |
[Rational approach to selection of antihypertensive therapy in persons with metabolic syndrome: efficacy of monotherapy with spirapril and its combination with retard form of nifedipine].
Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Calcium Channel Blockers; Cholesterol, LDL; Drug Th | 2006 |
High doses of lercanidipine are better tolerated than other dihydropyridines in hypertensive patients with metabolic syndrome: results from the TOLERANCE study.
Topics: Adolescent; Adult; Aged; Amlodipine; Antihypertensive Agents; Calcium Channel Blockers; Cross-Sectio | 2008 |